Disc Medicine (IRON) Non Operating Income (2022 - 2026)
Disc Medicine (IRON) posted quarterly Non Operating Income of $5.6 million for Q2 2026, down 9.7% year-over-year from $6.2 million in Q2 2025, and down 7.56% quarter-over-quarter from $6.1 million in Q1 2026.
Disc Medicine (IRON) Non Operating Income (2022 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Non Operating Income for 5 consecutive years, with $5.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income fell 9.7% year-over-year to $5.6 million; the TTM figure through Jun 2026 stood at $23.7 million (down 0.62% YoY), while the FY2025 annual figure was $24.2 million, up 16.8% from the prior year.
- Non Operating Income eased to $5.6 million in Q2 2026 per IRON's latest filing, from $6.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $6.5 million in Q4 2025 and bottomed at -$5.7 million in Q3 2022.
- Historically, Non Operating Income has averaged $4.0 million across 5 years, with a median of $5.1 million in 2023.
- On a YoY basis, Non Operating Income climbed as much as 2112.15% in 2023 and fell as far as 42.3% in 2023.
- Disc Medicine's Non Operating Income stood at $3.8 million in 2022, then surged by 63.28% to $6.2 million in 2023, then declined by 14.56% to $5.3 million in 2024, then gained by 23.88% to $6.5 million in 2025, then decreased by 14.02% to $5.6 million in 2026.
- Business Quant data shows IRON's Non Operating Income at $5.6 million in Q2 2026, $6.1 million in Q1 2026, and $6.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Disc Medicine | 3.02 Bn | 3.02 Bn | - | 5.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.61 Mn |
| Mar 31, 2026 | 6.07 Mn |
| Dec 31, 2025 | 6.53 Mn |
| Sep 30, 2025 | 5.48 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Mar 31, 2025 | 5.98 Mn |
| Dec 31, 2024 | 5.27 Mn |
| Sep 30, 2024 | 6.37 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Dec 31, 2023 | 6.17 Mn |
| Sep 30, 2023 | 4.86 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Mar 31, 2023 | 2.37 Mn |
| Dec 31, 2022 | 3.78 Mn |
| Sep 30, 2022 | -5.67 Mn |
| Jun 30, 2022 | 2.44 Mn |
| Mar 31, 2022 | 107,000.00 |